EANM guideline for ventilation/perfusion single-photon emission computed tomography (SPECT) for diagnosis of pulmonary embolism and beyond
- 1.2k Downloads
These guidelines update the previous EANM 2009 guidelines on the diagnosis of pulmonary embolism (PE). Relevant new aspects are related to (a) quantification of PE and other ventilation/perfusion defects; (b) follow-up of patients with PE; (c) chronic PE; and (d) description of additional pulmonary physiological changes leading to diagnoses of left ventricular heart failure (HF), chronic obstructive pulmonary disease (COPD) and pneumonia. The diagnosis of PE should be reported when a mismatch of one segment or two subsegments is found. For ventilation, Technegas or krypton gas is preferred over diethylene triamine pentaacetic acid (DTPA) in patients with COPD. Tomographic imaging with V/PSPECT has higher sensitivity and specificity for PE compared with planar imaging. Absence of contraindications makes V/PSPECT an essential method for the diagnosis of PE. When V/PSPECT is combined with a low-dose CT, the specificity of the test can be further improved, especially in patients with other lung diseases. Pitfalls in V/PSPECT interpretation are discussed. In conclusion, V/PSPECT is strongly recommended as it accurately establishes the diagnosis of PE even in the presence of diseases like COPD, HF and pneumonia and has no contraindications.
KeywordsPulmonary embolism Ventilation-perfusion SPECT CTPA V/P SPECT/CT COPD Left heart failure Pneumonia Chronic pulmonary embolism Pulmonary hypertension
Acute kidney injury
Chronic obstructive pulmonary disease
Computed tomography pulmonary angiography
Contrast media-induced nephropathy
Chronic thromboembolic pulmonary hypertension
Diethylene triamine pentaacetic acid
Deep venous thrombosis
European Association of Nuclear Medicine
Enzyme-linked immunosorbent assay
European Society of Cardiology
Radioactive krypton gas
Macroaggregated human albumin
Negative prediction value
Ordered subset expectation maximisation
Pulmonary embolism rule-out criteria
Prospective investigation of pulmonary embolism diagnosis
Positive predicitive value
The Society of Nuclear Medicine and Molecular Imaging
Ventilation and perfusion scan with planar imaging
Ventilation and perfusion scan
Ventilation and perfusion single-photon emission tomography
The European Association of Nuclear Medicine (EANM) will periodically develop new guidelines for nuclear medicine practice to promote the science of nuclear medicine and to improve the quality of service to patients throughout Europe. Each practice guideline, representing an EANM policy statement, has undergone an extensive consensus and review process.
The EANM has written and approved these guidelines to promote the use of nuclear medicine procedures of high quality. These guidelines are intended to assist practitioners in providing appropriate nuclear medicine care for patients. They are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care.
The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by medical professionals considering the unique circumstances of each case. Thus, there is no implication that an approach differing from the guidelines is below the standard of care. On the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set forth in the guidelines when, in the reasonable judgment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources or advances in knowledge or technology subsequent to publication of the guidelines.
These guidelines update the 2009 EANM guidelines on the diagnosis of pulmonary embolism (PE) [1, 2] for ventilation/perfusion single-photon emission tomography (V/PSPECT). Since the previous EANM guidelines, little new data has emerged with regard to the technical aspects of V/PSPECT. This document defines the role of V/PSPECT in the diagnosis of PE and other cardiopulmonary diseases.
Nonthrombotic emboli may be septic, fat, amniotic fluid and air. In this document, PE refers to venous thromboembolism (VTE). PE is an important and treatable illness caused by migration of thrombi to the pulmonary circulation, commonly from the veins of the lower extremities (deep vein thrombosis: DVT). PE can cause death in the acute phase or later through chronic thromboembolic pulmonary hypertension.
Although independent VTE risk factors and predictors of VTE recurrence have been identified, and effective primary and secondary prophylaxis is available, the occurrence of VTE seems to be relatively constant, or even increasing . Timely and accurate PE diagnosis is, therefore, essential.
Natural history of PE
The natural history of VTE has been extensively studied. Measurements of fibrinogen uptake were used by Kakkar et al. in the study evidencing that DVT developed in 30% of 132 patients undergoing surgery without prophylaxis . In most patients, DVT developed in the calf veins, propagating to the proximal leg veins in 13%. Forty-four percent of patients with proximal DVT developed PE. Evidence that DVT and PE are distinct manifestations of the same disease process, referred to as VTE, has been provided by observations showing that in the majority of patients with PE, DVT can be detected using sensitive methods. In patients with proven leg vein DVT, 40% have asymptomatic PE . However, whereas VTE can present with one or both of these two manifestations, DVT and PE, epidemiological differences between both are important. Mortality is higher for PE than for DVT . The International Cooperative Embolism Registry  aimed at determining baseline mortality rates and mechanisms of death reported a 3-month overall mortality rate of 15%; the factors significantly associated with increased mortality being systolic arterial hypotension, congestive heart failure, cancer, tachypnoea, right ventricular hypokinesia, COPD and age > 70 years. Resolution of PE is variable. Evidence shows that a majority of patients have unresolved PE at 6 months from diagnosis . Others report rapid resolution of a large PE within hours of the onset of heparin therapy . Fredin and Arborelius evidenced complete restoration of lung perfusion in patients with PE within 1 week of diagnosis . Based on this rapidly changing pattern of perfusion in PE, Coakley recommended that imaging tests for PE diagnosis should be carried out as soon as possible, preferably within 24 h after onset of symptoms .
Venous thromboembolism is a major cause of morbidity, mortality and hospitalisation [3, 12, 13, 14]. A model based on data from 6 European countries with a combined population of 310 million found approximately 466,000 cases of DVT and 296,000 cases of PE in 2004. These resulted in approximately 370,000 deaths, of which 7% were thought to be from diagnosed and treated VTE, 34% from sudden fatal PE and 59% from PE following undiagnosed VTE . Incidence for DVT and PE increases with age. VTE is rare prior to late adolescence [12, 15, 16].
One-third of PE episodes occur without any known risk factor and are classified as ‘unprovoked’ . The remaining ‘provoked’ PE episodes are secondary to a risk factor that may be temporary (e.g. surgery, trauma, immobilisation, pregnancy, oral contraceptive or hormone replacement therapy) or persistent (e.g. cancer or inherited thrombophilia) [12, 18, 19]. About 20% of all VTEs are cancer-related . Surgery and immobilisation each account for 15% of cases . Not infrequently, PE is without clinical manifestations .
The most frequent inherited risk factors are factor V and prothrombin (factor II) gene mutations. These have a European prevalence of 3–7% and 1–2%, respectively .
Following a PE, about one-third of patients show persistent pulmonary perfusion defects [24, 25, 26]. Chronic thromboembolic pulmonary hypertension (CTEPH) is the principal long-term complication of PE with an incidence of 0.1–4% .
PE frequently recurs, usually after discontinuation of anticoagulation (13% at 1 year, 23% at 5 years and 30% at 10 years) . Recurrence rate is higher after unprovoked VTE than after provoked VTE and higher after multiple episodes compared with a single event .
When unperfused regions are ventilated, there is an increase in the dead space . This is one of the reasons for dyspnoea. Hypoxia, frequently present in major PE, is caused by several mechanisms. The emboli occluding pulmonary end arteries alter the local equilibrium and, therefore, can lead to haemorrhage, atelectasis, pleural effusion and pleuritic pain. The lung has no pain fibres; thus, pain in PE is a symptom consequence of the involvement of the parietal pleura.
Moreover, there is also increased pulmonary vascular resistance that can produce right ventricular strain and failure, electromechanical dissociation, hypotension, syncope and sudden death. Pressure increase in the right atrium may lead to right-to-left shunt through a patent foramen ovale, contributing to hypoxaemia. The shunt can also produce paradoxical emboli, resulting in infarctions from venous thrombi in the systemic circulation, commonly the brain [29, 30, 31].
The clinical signs of PE range from asymptomatic to sudden death [12, 22]. Most patients with PE have symptoms including dyspnoea, tachypnoea, chest pain (pleuritic or retrosternal), cough, fever, haemoptysis, syncope, unilateral leg pain or swelling, palpitations, tachycardia or dizziness due to hypotension [32, 33]. Arterial hypotension and shock are rare signs indicating central massive PE and/or a severely reduced haemodynamic reserve, and these clinical signs and symptoms indicate high-risk PE. It is associated with particularly high early mortality . In the case of central PE, chest pain may have the characteristics of angina, probably because of right ventricular ischemia, and poses the problem of differentiating PE from acute coronary syndrome and aortic dissection .
The clinical features of PE are also common in patients without PE [32, 33], and the prevalence of PE in patients with clinically suspected VTE is only about 20% [34, 35]. Therefore, there is a risk that an undue number of patients might receive an unnecessary imaging procedure. Thus, assessments of clinical PE probability and d-dimer testing are important steps in clinical practice to guide decisions about who should be referred for imaging [31, 36]. The chest radiograph is useful for alternative diagnoses such as pneumothorax, pneumonia, COPD, lung cancer or pulmonary fibrosis.
Assessment of pretest clinical probability
Clinical probability for PE can be assessed empirically by clinical judgement (holistically) or by clinical prediction rules, foremost Wells’ and the revised Geneva scores [37, 38], which have been adequately validated [34, 35, 39] and recommended by EANM, the Society of Nuclear Medicine and Molecular Imaging and the European Society of Cardiology (ESC) [31, 40]. For both scores, simplified and validated versions are available [39, 41, 42, 43, 44]. Usually, patients are clinically stratified into two or three risk categories: unlikely/likely and low/intermediate/high with increasing prevalence of PE .
Plasma d-dimer (a breakdown product of fibrin clot) is not only regularly elevated in patients with venous thromboembolism but also in myocardial infarction, stroke, infection, inflammation, cancer and pregnancy. The specificity of d-dimer is, therefore, low, and a positive d-dimer test does not confirm PE. However, the d-dimer test is very sensitive. Therefore, when the d-dimer is below a predefined cut-off value (i.e. < 500 μg/L with correction for age), it can be used to exclude PE in patients with either low to intermediate or unlikely clinical probability [31, 46]. However, in old and persistent PE, d-dimer can be negative. In patients with a high or likely clinical probability, the d-dimer has no discriminating power and should not be measured .
In a recent randomised clinical trial including 1916 patients with suspected PE, considered by clinical judgement (holistically) to be at very low risk for PE, the use of the pulmonary embolism rule-out criteria (PERC) safely excluded PE . The PERC strategy may reduce the number of d-dimer tests in patients with very low clinical probability of PE , although caution is advised in using the PERC rule .
V/P imaging with SPECT (V/PSPECT) or in rare situations planar scintigraphy (V/Pplanar). Occasionally, perfusion-only lung scanning is performed. V/PSPECT may also be combined with low-dose computed tomography (CT), V/PSPECT/CT
Computed tomography of the pulmonary arteries (CTPA)
Invasive pulmonary angiography is no longer regarded as the gold standard for the diagnosis of PE because of its limited sensitivity and specificity and wide interobserver variability .
Basic principles of PE diagnosis
PE is in general an acute disease that should be diagnosed and treated without delay. V/PSPECT should, therefore, be performed according to a 1-day protocol. V/Pplanar should only be used when a patient for any reason cannot be examined by V/PSPECT.
Radiopharmaceuticals for V/PSPECT
Dosimetry of radiopharmaceuticals used for V/PSPECT
99mTc-DTPA (99mTc-diethylen-tetraamino-pentaacetate) is aerosolised from a water solution with a particle size of 1.2–2 μm. 99mTc-DTPA allows studies of alveolo-capillary permeability .
Technegas® is an aerosol of 99mTc-labelled solid graphite hydrophobic particles, with a diameter of about 0.005–0.2 μm . The particles tend to grow by aggregation and should, therefore, be used within 10 min after generation . The particle size is so small that the aerosol behaves nearly like a gas until it arrives at the periphery of the lung where the particles are deposited in bronchioli and alveoli, mostly by diffusion. Technegas® greatly reduces the problem of central deposition often encountered with 99mTc-DTPA. Technegas® facilitates interpretation, particularly in COPD . Hotspots are nevertheless seen in patients with severe airway obstruction. The penetration index for Technegas® may be used for grading of COPD severity [61, 62].
Krypton gas (81mKr) is an inert radioactive gas delivered from an 81Rb/81mKr generator. 81mKr has a half-life of 13 s. 81mKr is inhaled until it reaches a steady-state activity in the alveoli and then continuously during the whole imaging procedure. Due to the higher gamma energy (190 keV) of 81mKr compared with 99mTc (140 keV), ventilation and perfusion images can be acquired simultaneously. Because elimination of 81mKr from the alveoli is largely due to decay of the isotope rather than by expiration, regional activity at steady state accurately represents regional ventilation. In COPD, the inhalation time to reach steady state may, however, be too long to reach steady state. As the half-life of 81Rb is only 4.6 h, the need for daily delivery of the expensive cyclotron-produced generator limits the clinical use of 81mKr.
For perfusion scintigraphy, intravenously injected macroaggregates of 99mTc-labelled human albumin (MAA) with a diameter of 15–100 μm are nearly universally used. Intravenous injection of MAA leads to microembolisation of pulmonary precapillary arterioles and capillaries. Whilst 60,000 particles may suffice to reflect regional perfusion , about 400,000 labelled particles are usually injected. This leads to obstruction of a very small fraction of pulmonary vessels. Injection of no more than 100,000–200,000 particles is recommended for patients with known pulmonary hypertension, right-to-left heart shunt, pneumonectomy or after single lung transplantation. In infants and children, the number of particles is recommended to be further reduced according to weight .
Because of religious beliefs, it may be advisable to inform patients that MAA is a blood product.
Quality control and injection practice
As radiochemical purity varies, supernatant activity should be determined. As particles tend to settle, the vial should be shaken before use. Withdrawal of blood into the syringe should be avoided, as this will cause aggregation of MAA particles resulting in artefactual hotspots. The MAA suspension should be injected over 30 s, i.e. over several breaths, to promote distribution reflecting regional pulmonary perfusion. Patients should be in a supine position during inhalation, intravenous injection and during scanning.
Summary of ventilation/perfusion protocol for V/PSPECT. Patients should be in a supine position during inhalation, intravenous injection and during scanning
Radiopharmaceutical administered activity
Technegas® or DTPA 25–30 MBq to reach the lung
99mTc-MAA 120–160 MBq
0.005–0.2 μm or 1.2–2 μm
Time of imaging
≈ 11 min
≈ 5 min
Iterative reconstruction, e.g. OSEM with 8 subsets and 4 iterations
This principle leads to the lowest radiation exposure consistent with adequate image quality and, therefore, is in accordance with good medical practice. It is applied in commercially available software and hardware systems and is recommended in these guidelines. Deviations from these validated standards require complementary documentation. The use of low-energy high-resolution (LEHR) collimators would require either longer acquisition times or higher activities.
Iterative reconstruction is essential, e.g. ordered subset expectation maximisation (OSEM). For comparison between ventilation and perfusion including triangulation, the patient must be in the same position for the whole image acquisition.
Perfusion-only scintigraphy is recommended as a first step during the first 3 months of pregnancy and in the case of suspected massive PE (see below).
Standard software allows image presentation in coronal, sagittal and transverse projections as well as the presentation of rotating 3D images (Segami, Hermes, GE and others). Ventilation/perfusion quotient images may be derived from the primary images [65, 66]. Ventilation counts are normalised to perfusion counts before V/P quotient images are calculated. V/P quotient images facilitate diagnosis and quantification of PE extension. As attenuation is the same for ventilation and perfusion, V/P images do not require attenuation correction.
For quality control and fast orientation, an overview of ventilation and perfusion in coronal and sagittal slices is useful. For identification of matched and mismatched ventilation and perfusion changes and particularly for calculation of V/P quotient images, it is essential that ventilation and perfusion images are carefully aligned to each other. An example is shown in Fig. 2 of a patient with PE and multiple segmental perfusion defects, well delineated on V/P quotient images. This is facilitated by the one-session protocol with the patient in an unchanged position. Although helpful, V/P quotient images are not a prerequisite for high quality V/PSPECT. The option to triangulate between coronal, sagittal and transverse slices is valuable.
Interpretation and reporting of findings
Semiology of lung ventilation/perfusion pathology with V/PSPECT. Interpretation and differential diagnosis
Probability that the semiologic pattern is diagnostic
Level of evidence
≥ 2 subsegments
≤ 1 subsegment
Total lung unperfused
Very low (rare)
Very rare condition
Systematically antigravitational redistribution
Very low (rare)
Very rare condition, expert opinion
Segments or lobules
No stripe sign
Depends on clinical context
Pneumonia evolutioned stage
Segments or lobules
Pneumonia initial stage
No stripe sign
Criteria for acute pulmonary embolism
• V/P mismatch of at least one segment or two subsegments in keeping with the pulmonary vascular anatomy (wedge-shaped defects with the base projecting to the lung periphery).
• Normal perfusion pattern in keeping with the anatomic boundaries of the lungs.
• Matched or reversed-mismatched V/P defects of any size, shape or number in the absence of mismatch.
• Mismatch that does not follow a lobar, segmental or subsegmental pattern.
Nondiagnostic for PE:
• Widespread V/P abnormalities not typical of specific diseases.
As proposed in the 2009 EANM guidelines, the diagnostic cut-off to consider a V/PSPECT positive for PE should be 1 segmental or 2 subsegmental mismatched defects. This principle is further supported , and its safety was confirmed in large studies [67, 68, 69]. A single subsegmental mismatched perfusion defect should be reported but does not fulfil diagnostic criteria for PE. In some cases, PE may be found on CTPA in such patients, but clinical significance is not documented. Pulmonary arteries and capillary beds uniquely possess fibrinolytic properties that both trap and lyse small subsegmental clots, suggesting that small PEs are a common physiological phenomenon.
Recommendations from the ESC suggest an individualised approach; patients can be managed conservatively if the presence of deep vein thrombosis has been excluded . Patients with a Wells score > 4 have a 4-fold increased risk of adverse outcome with one or multiple emboli in subsegmental arteries .
Applying these principles of interpretation, recent V/PSPECT studies amounting to over 5000 cases report a negative predictive value of 97–99%, sensitivities of 96–99% and specificities of 96–98% for PE diagnosis. Rates of nondiagnostic findings were 1–4% [61, 68, 69, 71, 72, 73, 74, 75, 76, 77, 78].
Pitfalls in the interpretation of V/PSPECT
Technical artefacts may arise from preinjection handling of the 99mTc-MAA. The withdrawal of blood into the syringe that contains the solution of 99mTc-MAA can cause the aggregation of particles that can produce hotspots in the images. A similar consequence can appear from failure to resuspend 99mTc-MAA particles before the administration.
Planar imaging may underestimate the presence or extent of perfusion abnormalities because of normal perfusion masking embolised regions, also known as the shine through of normal areas. This problem is eliminated by V/PSPECT.
Technegas® is preferred over liquid aerosols in patients with COPD. Moreover, in rare patients with emphysema, Technegas® particles are trapped in bullae in which perfusion is absent. This causes a pattern that may be mistaken for a mismatch [76, 79].
In rare cases, vasculitis and congenital vascular anomalies may lead to segmental/lobar mismatches.
Mismatched perfusion defects without a clear segmental character may be seen in older, partly resolved PE, but not related to acute PE. These nonsegmental mismatched defects are observed in several lung disorders including lung cancer, mediastinal lymphadenopathy, postradiation pneumonitis/fibrosis and heart failure. V/PSPECT facilitates the identification of segmental perfusion defects, which are particularly well visualised when using rotating 3D volumetric images.
Unilateral absence of perfusion in a whole lung with preserved ventilation and without any V/P mismatch in the other lung is generally not due to PE [80, 81]. In such cases, chest CT may reveal the presence of other pathologies such as tumour, aortic dissection, other mediastinal processes or congenital pulmonary vascular abnormalities.
The ‘rind’ artefact seen in ventilation SPECT represents a band of increased activity along the posterior (dependent) portion of the lung. This is probably produced by dynamic changes in the lung volume during the acquisition [57, 82].
Fissure artefacts are a common finding along the line of the oblique fissure, especially in perfusion SPECT. It may produce a nonsegmental mismatch .
Quantification of PE extent
The extent of PE is an independent risk factor for PE recurrence [83, 84, 85]. Quantification of PE may be useful for the management of patients with acute PE . V/PSPECT is particularly suitable for quantification. The number of segments and subsegments indicating mismatch typical of PE can be counted and expressed as a percentage of the total lung parenchyma. However, as the volume of each segment and subsegment is different, this calculation is approximate providing a semiquantification of the percentage of the total lung parenchyma affected. Furthermore, areas with ventilation abnormalities can be recognised allowing for the assessment of the degree of total lung function affected. In haemodynamically stable patients with PE, outpatient management is safe provided that the embolic burden, quantified using V/PSPECT, is included in the treatment decision algorithm .
Assess therapy effect
Differentiate between new and old PE when there is a suspicion of PE recurrence
Explain physical incapacity after PE
Applicability to all patients
Low radiation dose
High sensitivity to allow estimation of resolution of even small emboli and occurrence of new ones
V/PSPECT seems ideally suited for follow-up of PE because small and large emboli are both recognised, allowing a detailed study of regression or progression of the thrombotic disease [87, 88, 89]. Furthermore, the low radiation exposure enables repeat studies. Obviously, using the same method for diagnosis and follow-up is advantageous. Research in this area is especially indicated and a predischarge V/PSPECT can be recommended to help identify patients in need of life-long treatment.
The CT is usually performed as a low-dose CT scan without contrast enhancement. The additional radiation dose is approximately 1–2 mSv, so that the whole V/PSPECT/CT acquisition results in approximately 3–4 mSv. To reduce misalignment between the SPECT and CT images, it is proposed that CT scans are acquired during continuous shallow breathing . Obviously, this will affect evaluation of structures particularly in basal regions, causing artefacts.
Further studies of V/PSPECT/CT to define its value according to good clinical practice in various categories of patients seem merited. In patients with COPD, the added value of V/PSPECT/CT has been validated .
Computed tomography angiography of the pulmonary artery (CTPA) is imaging of the pulmonary arteries during the passage of intravenously injected iodinated contrast material. Pulmonary emboli are visualsed as so-called filling defects caused by emboli within otherwise homogenously contrast-filled pulmonary arteries. CTPA is easy to perform in a few minutes.
CTPA needs to be embedded in decision strategies that are based on the assessment of clinical PE likelihood . CTPA confirms the diagnosis of PE in clinically high probability patients (PPV > 95%). In the case of high pretest probability of PE and a negative CTPA, current data on diagnostic accuracy are inconsistent [94, 95, 96]; CTPA is overused in a great number of patients with low prevalence of PE [97, 98]. A PE located centrally in the pulmonary circulation can be detected by CTPA with a high PPV. The PPV decreases at segmental and subsegmental levels . When clinical probability of PE is low or intermediate, CTPA may overdiagnose PE, leading to a low NPV .
CTPA has the potential to visualise additional pathologies other than PE such as pneumothorax, pneumonia, interstitial lung disease, pleural disease, aortic dissection and pathologies of the spine and rib cage. In the case of PE, CT is able to depict signs of right heart strain which is of prognostic importance [99, 100, 101].
Risks of CTPA
Iodine hypersensitivity. Severe pseudoallergic reactions are generally very rare (approx. 0.04%, rarely fatal ). In an emergency scenario when CT cannot be withheld, intravenous premedication may be suitable.
Thyroid dysfunction. Induction of hyperthyroidism and in rare cases also hypothyroidism is another complication associated with iodinated contrast media . In an iodine-deficient geographical region, 2% of patients developed subclinical hyperthyroidism . In unselected patients, overt hyperthyroidism occurred in 0.25% within 12 weeks . Iodine-induced thyrotoxicosis is often overlooked in the elderly , and in the worst case, it may even cause a thyroid storm with cardiac arrest . Risk factors are (potentially undiagnosed) Graves’ disease and/or thyroid autonomy . Patients with thyroid storm should not receive iodinated contrast media at all; in other cases, premedication with oral sodium perchlorate (and thiamazole) may be helpful. Under emergency conditions, this treatment may be initiated directly after contrast exposure. Thyroid function is routinely monitored prior to contrast application in the vast majority of radiological institutions through serum baseline TSH.
Renal dysfunction. The most severe complication of CTPA is contrast media-induced nephropathy (CIN) or contrast-induced acute kidney injury (CI-AKI). CI-AKI is defined as an increase in serum creatinine within 48–72 h after intravenous administration of low- or isoosmolarity iodinated contrast media. It carries a risk of chronic renal insufficiency, dialysis and death [100, 109]. The assumption of causality between intravenous contrast media administration and AKI has been challenged in recent publications, but data are controversial. The baseline glomerular filtration rate (eGFR) was found to be an independent predictor of AKI . In two multivariate analyses, patients with an eGFR ≤ 43.6 mL/min  or eGFR < 60 mL/min , respectively, had the potential to develop CI-AKI. The odds ratios in the incidence of CI-AKI between contrast-enhanced CT and noncontrast CT increased below an eGFR < 30 mL/min . In two meta-analyses, contrast-enhanced CT, compared with non-contrast-enhanced CT, was not significantly associated with AKI [114, 115]. In a large single-centre retrospective cohort study, the probability of developing AKI was 10.6%, 10.2% and 10.9% in the contrast-enhanced, unenhanced and non-CT group . However, a selection bias must be considered as only a minority of patients with a baseline serum creatinine > 1.5 mg/dL received contrast media and factors that may have influenced the clinical decision to administer contrast media could not be perceived. Randomisation of patients to receive intravenous contrast media, once not considered ethically feasible, will be necessary to fully understand the role of contrast media in precipitation of renal dysfunction . Current guidelines consider intravenous contrast administration to be safe to a creatinine clearance of 30 mL/min/1.73 m2 . In almost every radiological institution, a baseline serum creatinine level and/or eGFR is determined prior to intravenous contrast administration to identify patients at risk. CI-AKI was considered to be the third most common cause in hospital acquired AKI ; now strong evidence is provided that the incidence of CI-AKI is substantially lower . AKI is a multifactorial entity, and usually more than one risk factor (contrast media, nephrotoxic drugs, hypertension, age > 70 years, reduced cardiac output, diabetes mellitus and others) is involved .
Comparison of V/PSPECT and CTPA (see also Table 4)
Summary of the pros and cons for the two principal methods to diagnose PE
Makes CTPA indispensable
Up to 50%
Makes V/PSPECT indispensable
Rate of nondiagnostic studies
In high clinical probability, 40% needs further exam
V/PSPECT and CTPA equivalent
Effective radiation dose
Absorbed breast radiation dose
≈ 0.8 mGy
V/PSPECT crucial for young women
Highest documented rate—V/PSPECT
Diagnostics of chronic pulmonary embolism
Not useful but needed prior to surgery?
V/PSPECT is gold standard
Follow-up and research
V/PSPECT offers quantitative data
Feasibility and rate of nondiagnostic studies
Feasibility of CTPA is restricted by the need to use intravenous iodinated contrast media. Whilst the general risk of CI-AKI seems to be overestimated  and iodine-induced thyrotoxicosis may be prevented by premedication, the residual risks are of a serious nature. Elevated serum creatinine and a suppressed TSH are relative contraindications to CTPA provided that V/PSPECT is available [52, 96]. High flow rates of contrast medium are a precondition for CTPA, but cannot be achieved in all patients. Motion artefacts reduce spatial resolution. In the PIOPED II trial, CTPA was inconclusive in 6.2% of patients because of poor image quality, in a subgroup this was 10.6% . An increase of detector rows in CT improves resolution of CTPA, but the number of inconclusive results remained at 10% in both the 4-row and 64-row cohort, mostly due to movement artefacts and suboptimal contrast opacification . In pregnant patients and those with a very low prevalence of PE (3.3%), inconclusive results were seen in 5.9% . Nondiagnostic studies with V/PSPECT may be obtained with conventional radioaerosol in patients with severe COPD, but this restriction has been mostly eliminated by the use of Technegas® [68, 69, 119, 120]. In conclusion, if contrast media-related risks are considered, feasibility of CTPA is restricted in many more patients than with V/PSPECT.
In haemodynamically unstable patients, CTPA is often recommended [31, 130]. However, if a gamma camera is available, perfusion-only scintigraphy, even a single planar image, is adequate to exclude massive PE .
Accuracy of PE diagnosis
The lack of a satisfactory gold standard for making the diagnosis of PE poses difficulties for the assessment of sensitivity, specificity and accuracy of all diagnostic methods. Follow-up of patients for recurrence of PE as a predictor of false negative results may overcome this limitation. The comparison of V/PSPECT and CTPA shows controversies. On one side, no performance difference between V/PSPECT and CTPA was seen . In other studies, V/PSPECT is proposed to be superior to CTPA in cases with other underlying lung diseases preventing the diagnosis of PE with CTPA. V/PSPECT more often provided a diagnosis of PE in patients with high clinical suspicion of PE and in the presence of indeterminate CTPA imaging (sensitivity 93% vs. 83%) [68, 94, 131, 132].
The mean sensitivity (equivalent) was > 95% for the both methods. The results do not reflect true sensitivity of the imaging test, since most PE are single events, not recorded by follow-up. On the other hand, sensitivities derived from relapse rates clearly indicate that both V/PSPECT and 16- to 64-row CTPA are able to recognise larger PE with a tendency to recurrent episodes of PE. An error rate of about 5% may be caused by false negative results of the imaging test with subsequent PE relapse, but may also reflect true negative results with subsequent primary PE events. Large multicentre management outcome studies based on V/PSPECT with a standardised diagnostic algorithm defined a priori are needed to differentiate this.
In a systematic review and meta-analysis, diagnostic performance of V/PSPECT was equivalent to CTPA . In head-to-head comparison studies, V/PSPECT was superior to CTPA using ROC analysis . This applies particularly in cases with other underlying lung diseases and when the diagnosis of PE could not be established with CTPA [68, 94, 132, 141]. V/PSPECT more often provided a diagnosis of PE in patients with a high clinical suspicion of PE and in the presence of indeterminate CTPA (sensitivity 93% vs. 83%) . Superior sensitivity of V/PSPECT is best seen in patients with chronic pulmonary embolism where V/PSPECT has reference status , but CTPA and right heart catheterisation are also essential for patient care.
In conclusion, both techniques display specific advantages and shortcomings. V/PSPECT is superior to CTPA in cases with underlying other lung diseases and when the diagnosis of PE cannot be established with CTPA [68, 94, 131, 132].
A key objective of imaging PE is to minimise radiation exposure without sacrificing image quality and diagnostic accuracy. The amounts of radiation involved must be considered together with imaging protocols. Table 1 gives basic data on radiation exposure for V/PSPECT. With the recommended activities for ventilation and perfusion, the effective dose is 2 mSv.
In a systematic review and meta-analysis of the literature, radiation exposure was 2.12 mSv for V/PSPECT per correct diagnosis compared with 4.96 mSv for CTPA . In clinical routine, radiation doses between 3.5 and 13.2 mSv have been reported for CTPA [122, 123, 124]. Automated data collection as volume CT dose index and dose-length product, averaged to effective doses, varies considerably within and across facilities. Primary factors that influence dose variations are patient size (weight and chest diameter), multiphase scanning and institutional protocol choices . In general, higher effective doses (> 5 mSv) are reported from automatically collected data [125, 126, 127].
The most critical organ in CTPA is the female breast. Absorbed radiation doses to the female breast ranging from 8.6 to 44 mSv have been reported [79, 128, 143]. Tube current modulation is able to decrease the breast dose from 51.5 to 8.6 mSv , whilst shielding is less effective . Absorbed radiation dose to the female breast from V/PSPECT is < 1 mSv . Fetal-absorbed doses for V/PSPECT and CTPA are similar and so small that they are unlikely to be clinically significant [79, 128, 145].
In conclusion, effective and absorbed doses are lower for V/PSPECT than for CTPA. The difference is of particular importance for the female breast, particularly in young women and critically so during pregnancy. Fetal doses are low and similar for both methods.
Additional diagnostic contributions of V/PSPECT
Chronic obstructive pulmonary disease
Grade 1: uneven aerosol distribution through the lung seen in mild COPD.
Grade 2: uneven aerosol distribution and reduced Technegas® penetration to the periphery, with deposition of aerosols in small airways, seen as hotspots. This indicates moderate COPD.
Grade 3: a severely impaired Technegas® penetration to the periphery and a central deposition of Technegas® in large airways, usually with large areas of reduced/absent ventilation. This indicates severe COPD. Figure 8 presents a case with severe COPD, emphysema and PE.
Left heart failure
Chronic pulmonary embolism and chronic thromboembolic pulmonary hypertension
V/Pscan with a sensitivity of 96% and specificity of 90% is a mainstay in the diagnosis of CTEPH, since CTPA has a sensitivity of only ≈ 50% . The higher sensitivity of V/PSPECT compared with CTPA has been confirmed ; agreement between CTPA and scintigraphy ranged from fair (κ = 0.31) to slight (κ = 0.09) .
After diagnosis of CTEPH, CTPA and right heart catheterisation are important for management decisions about therapy.
Lung cancer radiotherapy planning
Radiation therapy, alone or in combination with other treatment, plays an important role in the management of lung cancer. ‘Functional image-guided lung avoidance radiotherapy’ is an emerging concept aimed at delivering a high radiation dose to the lung cancer tumour volume whilst minimising irradiation to the uninvolved functional lung tissue. In the future, V/PSPECT could become an interesting technique to provide the functional information needed for the planning of such treatment .
The incidence of PE in pregnancy is about fivefold higher than in nonpregnant females of a similar age and is the leading nonobstetric cause of death during pregnancy in developed countries. The incidence of PE and DVT is about 1 and 3‰, respectively . The incidence is similar in all 3 trimesters . The diagnostic accuracy of any test is compromised by a low prevalence of PE in this collective [147, 173].
CTPA leads to unique radiation hazards to the maternal breast .
To avoid unnecessary irradiation, venous compression ultrasonography can be considered. However, the diagnostic yield can be low .
An increased blood volume and cardiac output shortens the arrival time of intravenous contrast in the pulmonary vessels, necessitating adjustments in triggered scan delays [178, 181]. Transient influx of unopacified blood from the inferior vena cava has also been identified as a cause for poor-quality CTPA [178, 182]. Nondiagnostic CTPA scans occur in 6–36% of patients, whilst alternative diagnoses were identified in 2–13% [145, 178, 183, 184]. Prenatal exposure to iodinated contrast media is not a risk factor for neonatal thyroid dysfunction .
To minimise radiation, a 2-day protocol is recommended. Perfusion-only SPECT is performed on day 1, with only 50 MBq 99mTc-MAA. Because of the low incidence of pulmonary disorders in pregnant women, PE is usually excluded based on a normal perfusion pattern . In the case of an abnormal perfusion pattern, anticoagulation therapy can be started until a ventilation study is performed on day 2, using a lung-deposited activity of 20–30 MBq. This strategy leads to a high sensitivity and specificity of the examination [145, 147]. After the first trimester, the standard 1-day V/PSPECT protocol may be considered.
Fetal doses for both CTPA and perfusion SPECT are ≤ 0.12 mGy [145, 187, 188, 189, 190]. The maternal absorbed dose, mainly to the breast, differs significantly and may range from 5 to 20 mSv for CTPA [121, 125, 127, 145, 191, 192] and 0.5–0.8 mSv for V/PSPECT [145, 147].
‘This guideline summarizes the views of the Cardiology Committee of the EANM/European Association of Vascular Medicine, experts in radiology and cardiology, and reflects recommendations for which the EANM cannot be held responsible. The recommendations should be taken into context of good practice of nuclear medicine and do not substitute for national and international legal or regulatory provisions’.
‘The guidelines were brought to the attention of all other EANM Committees and to the European National Societies of Nuclear Medicine. The comments and suggestions from the EANM Committees and from the European National Societies are highly appreciated and have been considered for this Guideline’.
The images included in the manuscript are from Lund University Hospital.
Open access funding provided by Lund University.
Compliance with ethical standards
The authors declare that they have no conflict of interest.
- 1.Bajc M, Neilly JB, Miniati M, Schuemichen C, Meignan M, Jonson B. EANM guidelines for ventilation/perfusion scintigraphy: Part 1. Pulmonary imaging with ventilation/perfusion single photon emission tomography. Eur J Nucl Med Mol Imaging. 2009;36:1356–70. https://doi.org/10.1007/s00259-009-1170-5.CrossRefPubMedGoogle Scholar
- 2.Bajc M, Neilly JB, Miniati M, Schuemichen C, Meignan M, Jonson B. EANM guidelines for ventilation/perfusion scintigraphy: Part 2. Algorithms and clinical considerations for diagnosis of pulmonary emboli with V/P(SPECT) and MDCT. Eur J Nucl Med Mol Imaging. 2009;36:1528–38. https://doi.org/10.1007/s00259-009-1169-y.CrossRefPubMedGoogle Scholar
- 6.White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107:I4–8. https://doi.org/10.1161/01.CIR.0000078468.11849.66.CrossRefPubMedGoogle Scholar
- 14.Prabhu W, Soukas PA. Pulmonary embolism in 2017: increasing options for increasing incidence. R I Med J (2013). 2017;100:27–32.Google Scholar
- 30.Goldhaber SZ, Elliott CG. Acute pulmonary embolism: part I: epidemiology, pathophysiology, and diagnosis. Circulation. 2003;108:2726–9. https://doi.org/10.1161/01.cir.0000097829.89204.0c.CrossRefPubMedGoogle Scholar
- 33.Pollack CV, Schreiber D, Goldhaber SZ, Slattery D, Fanikos J, O’Neil BJ, et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardiol. 2011;57:700–6. https://doi.org/10.1016/j.jacc.2010.05.071.CrossRefPubMedGoogle Scholar
- 34.Ceriani E, Combescure C, Le Gal G, Nendaz M, Perneger T, Bounameaux H, et al. Clinical prediction rules for pulmonary embolism: a systematic review and meta-analysis. Journal of thrombosis and haemostasis : JTH. 2010;8:957–70. https://doi.org/10.1111/j.1538-7836.2010.03801.x.CrossRefPubMedGoogle Scholar
- 35.Lucassen W, Geersing GJ, Erkens PM, Reitsma JB, Moons KG, Buller H, et al. Clinical decision rules for excluding pulmonary embolism: a meta-analysis. Ann Intern Med. 2011;155:448–60. https://doi.org/10.7326/0003-4819-155-7-201110040-00007.CrossRefPubMedGoogle Scholar
- 39.Douma RA, Mos IC, Erkens PM, Nizet TA, Durian MF, Hovens MM, et al. Performance of 4 clinical decision rules in the diagnostic management of acute pulmonary embolism: a prospective cohort study. Ann Intern Med. 2011;154:709–18. https://doi.org/10.7326/0003-4819-154-11-201106070-00002.CrossRefPubMedGoogle Scholar
- 40.Raja AS, Greenberg JO, Qaseem A, Denberg TD, Fitterman N, Schuur JD, et al. Evaluation of patients with suspected acute pulmonary embolism: best practice advice from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2015;163:701–11. https://doi.org/10.7326/M14-1772.CrossRefPubMedGoogle Scholar
- 48.Freund Y, Cachanado M, Aubry A, Orsini C, Raynal PA, Féral-Pierssens AL, et al. Effect of the pulmonary embolism rule-out criteria on subsequent thromboembolic events among low-risk emergency department patients: the PROPER randomized clinical trial. Jama. 2018;319:559–66. https://doi.org/10.1001/jama.2017.21904.CrossRefPubMedPubMedCentralGoogle Scholar
- 52.Gutte H, Mortensen J, Jensen CV, Johnbeck CB, von der Recke P, Petersen CL, et al. Detection of pulmonary embolism with combined ventilation-perfusion SPECT and low-dose CT: head-to-head comparison with multidetector CT angiography. J Nucl Med. 2009;50:1987–92. https://doi.org/10.2967/jnumed.108.061606.CrossRefPubMedGoogle Scholar
- 53.Le Roux PY, Pelletier-Galarneau M, De Laroche R, Hofman MS, Zuckier LS, Roach P, et al. Pulmonary scintigraphy for the diagnosis of acute pulmonary embolism: a survey of current practices in Australia, Canada, and France. J Nucl Med. 2015;56:1212–7. https://doi.org/10.2967/jnumed.115.157743.CrossRefPubMedGoogle Scholar
- 61.Bajc M, Markstad H, Jarenbäck L, Tufvesson E, Bjermer L, Jögi J. Grading obstructive lung disease using tomographic pulmonary scintigraphy in patients with chronic obstructive pulmonary disease (COPD) and long-term smokers. Ann Nucl Med. 2015;29:91–9. https://doi.org/10.1007/s12149-014-0913-y.CrossRefPubMedGoogle Scholar
- 62.Jögi J, Ekberg M, Jonson B, Bozovic G, Bajc M. Ventilation/perfusion SPECT in chronic obstructive pulmonary disease: an evaluation by reference to symptoms, spirometric lung function and emphysema, as assessed with HRCT. Eur J Nucl Med Mol Imaging. 2011;38:1344–52. https://doi.org/10.1007/s00259-011-1757-5.CrossRefPubMedGoogle Scholar
- 66.Bajc M, Olsson CG, Palmer J, Jonson B. Quantitative ventilation/perfusion SPECT (QV/PSPECT): a primary method for diagnosis of pulmonary embolism. In: Freeman LM, editor. Nuclear Medicine Annual. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 173–86.Google Scholar
- 73.Le Duc-Pennec A, Le Roux PY, Cornily JC, Jaffrelot M, Delluc A, de Saint-Martin L, et al. Diagnostic accuracy of single-photon emission tomography ventilation/perfusion lung scan in the diagnosis of pulmonary embolism. Chest. 2012;141:381–7. https://doi.org/10.1378/chest.11-0090.CrossRefPubMedGoogle Scholar
- 77.Quirce R, Ibáñez-Bravo S, Jiménez-Bonilla J, Martínez-Rodríguez I, Martínez-Amador N, Ortega-Nava F, et al. Contribution of V/Q SPECT to planar scintigraphy in the diagnosis of pulmonary embolism. Rev Esp Med Nucl Imagen Mol. 2014;33:153–8. https://doi.org/10.1016/j.remn.2013.12.001.CrossRefPubMedGoogle Scholar
- 87.Begic A, Jögi J, Hadziredzepovic A, Kucukalic-Selimovic E, Begovic-Hadzimuratovic S, Bajc M. Tomographic ventilation/perfusion lung scintigraphy in the monitoring of the effect of treatment in pulmonary embolism: serial follow-up over a 6-month period. Nucl Med Commun. 2011;32:508–14. https://doi.org/10.1097/MNM.0b013e328344dfd5.CrossRefPubMedGoogle Scholar
- 91.Le Roux PY, Robin P, Delluc A, Abgral R, Palard X, Tissot V, et al. Additional value of combining low-dose computed tomography to V/Q SPECT on a hybrid SPECT-CT camera for pulmonary embolism diagnosis. Nucl Med Commun. 2015;36:922–30. https://doi.org/10.1097/mnm.0000000000000351.CrossRefPubMedGoogle Scholar
- 92.Palmowski K, Oltmanns U, Kreuter M, Mottaghy FM, Palmowski M, Behrendt FF. Diagnosis of pulmonary embolism: conventional ventilation/perfusion SPECT is superior to the combination of perfusion SPECT and nonenhanced CT. Respiration. 2014;88:291–7. https://doi.org/10.1159/000365817.CrossRefPubMedGoogle Scholar
- 93.Jögi J, Markstad H, Tufvesson E, Bjermer L, Bajc M. The added value of hybrid ventilation/perfusion SPECT/CT in patients with stable COPD or apparently healthy smokers. Cancer-suspected CT findings in the lungs are common when hybrid imaging is used. Int J Chron Obstruct Pulmon Dis. 2015;10:25–30. https://doi.org/10.2147/copd.S73423.CrossRefPubMedGoogle Scholar
- 95.Robert-Ebadi H, Glauser F, Planquette B, Moumneh T, Le Gal G, Righini M. Safety of multidetector computed tomography pulmonary angiography to exclude pulmonary embolism in patients with a likely pretest clinical probability. J Thromb Haemost. 2017;15:1584–90. https://doi.org/10.1111/jth.13746.CrossRefPubMedGoogle Scholar
- 97.Feng LB, Pines JM, Yusuf HR, Grosse SD. U.S. trends in computed tomography use and diagnoses in emergency department visits by patients with symptoms suggestive of pulmonary embolism, 2001-2009. Acad Emerg Med. 2013;20:1033–40. https://doi.org/10.1111/acem.12221.CrossRefPubMedPubMedCentralGoogle Scholar
- 101.Stein PD, Matta F, Sedrick JA, Saleh T, Badshah A, Denier JE. Ancillary findings on CT pulmonary angiograms and abnormalities on chest radiographs in patients in whom pulmonary embolism was excluded. Clin Appl Thromb Hemost. 2012;18:201–5. https://doi.org/10.1177/1076029611416640.CrossRefPubMedGoogle Scholar
- 102.ACR manual on contrast media. Version 10.3. 2017.Google Scholar
- 104.Jarvis C, Simcox K, Tamatea JA, McAnulty K, Meyer-Rochow GY, Conaglen JV, et al. A low incidence of iodine-induced hyperthyroidism following administration of iodinated contrast in an iodine-deficient region. Clin Endocrinol (Oxf). 2016;84:558–63. https://doi.org/10.1111/cen.12818.CrossRefGoogle Scholar
- 108.Dave A, Ludlow J, Malaty J. Thyrotoxicosis: an under-recognised aetiology. BMJ Case Rep. 2015;2015. https://doi.org/10.1136/bcr-2014-208119.
- 110.Caspi O, Habib M, Cohen Y, Kerner A, Roguin A, Abergel E, et al. Acute kidney injury after primary angioplasty: is contrast-induced nephropathy the culprit? J Am Heart Assoc. 2017;6. https://doi.org/10.1161/JAHA.117.005715.
- 111.Kume K, Yasuoka Y, Adachi H, Noda Y, Hattori S, Araki R, et al. Impact of contrast-induced acute kidney injury on outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Cardiovasc Revasc Med. 2013;14:253–7. https://doi.org/10.1016/j.carrev.2013.07.009.CrossRefPubMedGoogle Scholar
- 112.Celik O, Ozturk D, Akin F, Ayca B, Yalcin AA, Erturk M, et al. Association between contrast media volume-glomerular filtration rate ratio and contrast-induced acute kidney injury after primary percutaneous coronary intervention. Angiology. 2015;66:519–24. https://doi.org/10.1177/0003319714542277.CrossRefPubMedGoogle Scholar
- 113.Davenport MS, Khalatbari S, Cohan RH, Dillman JR, Myles JD, Ellis JH. Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate. Radiology. 2013;268:719–28. https://doi.org/10.1148/radiol.13122276.CrossRefPubMedGoogle Scholar
- 115.McDonald JS, McDonald RJ, Carter RE, Katzberg RW, Kallmes DF, Williamson EE. Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified by baseline-estimated glomerular filtration rate. Radiology. 2014;271:65–73. https://doi.org/10.1148/radiol.13130775.CrossRefPubMedGoogle Scholar
- 116.Hinson JS, Mistry B, Hsieh YH, Risko N, Scordino D, Paziana K, et al. Using the electronic medical record to reduce unnecessary ordering of coagulation studies for patients with chest pain. West J Emerg Med. 2017;18:267–9. https://doi.org/10.5811/westjem.2016.12.31927.CrossRefPubMedPubMedCentralGoogle Scholar
- 117.ESUR guidelines on contrast media. Version 10.0. 2018.Google Scholar
- 119.Bajc M, Chen Y, Wang J, Li XY, Shen WM, Wang CZ, et al. Identifying the heterogeneity of COPD by V/P SPECT: a new tool for improving the diagnosis of parenchymal defects and grading the severity of small airways disease. Int J Chron Obstruct Pulmon Dis. 2017;12:1579–87. https://doi.org/10.2147/copd.S131847.CrossRefPubMedPubMedCentralGoogle Scholar
- 120.Nasr A, Lindqvist A, Bajc M. Ventilation defect typical for COPD is frequent among patients suspected for pulmonary embolism but does not prevent the diagnosis of PE by VP SPECT. EC Pulmonol Respir Med. 2017;4:85–91.Google Scholar
- 121.Phillips JJ, Straiton J, Staff RT. Planar and SPECT ventilation/perfusion imaging and computed tomography for the diagnosis of pulmonary embolism: a systematic review and meta-analysis of the literature, and cost and dose comparison. Eur J Radiol. 2015;84:1392–400. https://doi.org/10.1016/j.ejrad.2015.03.013.CrossRefPubMedGoogle Scholar
- 122.Bucher AM, Kerl MJ, Albrecht MH, Beeres M, Ackermann H, Wichmann JL, et al. Systematic comparison of reduced tube current protocols for high-pitch and standard-pitch pulmonary CT angiography in a large single-center population. Acad Radiol. 2016;23:619–27. https://doi.org/10.1016/j.acra.2016.01.003.CrossRefPubMedGoogle Scholar
- 123.De Zordo T, von Lutterotti K, Dejaco C, Soegner PF, Frank R, Aigner F, et al. Comparison of image quality and radiation dose of different pulmonary CTA protocols on a 128-slice CT: high-pitch dual source CT, dual energy CT and conventional spiral CT. Eur Radiol. 2012;22:279–86. https://doi.org/10.1007/s00330-011-2251-y.CrossRefPubMedGoogle Scholar
- 131.Ibáñez-Bravo S, Banzo I, Quirce R, Martínez-Rodríguez I, Jímenez-Bonilla J, Martínez-Amador N, et al. Ventilation/perfusion SPECT lung scintigraphy and computed tomography pulmonary angiography in patients with clinical suspicion of pulmonary embolism. Rev Esp Med Nucl Imagen Mol. 2016;35:215–20. https://doi.org/10.1016/j.remn.2015.12.008.CrossRefPubMedGoogle Scholar
- 134.Mos IC, Douma RA, Erkens PM, Kruip MJ, Hovens MM, van Houten AA, et al. Diagnostic outcome management study in patients with clinically suspected recurrent acute pulmonary embolism with a structured algorithm. Thromb Res. 2014;133:1039–44. https://doi.org/10.1016/j.thromres.2014.03.050.CrossRefPubMedGoogle Scholar
- 136.van der Hulle T, Cheung WY, Kooij S, Beenen LFM, van Bemmel T, van Es J, et al. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. Lancet. 2017;390:289–97. https://doi.org/10.1016/S0140-6736(17)30885-1.CrossRefPubMedGoogle Scholar
- 137.van der Hulle T, van Es N, den Exter PL, van Es J, Mos ICM, Douma RA, et al. Is a normal computed tomography pulmonary angiography safe to rule out acute pulmonary embolism in patients with a likely clinical probability? A patient-level meta-analysis. Thromb Haemost. 2017;117:1622–9. https://doi.org/10.1160/TH17-02-0076.CrossRefPubMedGoogle Scholar
- 138.van der Pol LM, van der Hulle T, Mairuhu ATA, Huisman MV, Klok FA. Combination of pulmonary embolism rule-out criteria and YEARS algorithm in a European cohort of patients with suspected pulmonary embolism. Thromb Haemost. 2018;118:547–52. https://doi.org/10.1055/s-0038-1623535.CrossRefPubMedGoogle Scholar
- 141.Leuschner G, Wenter V, Milger K, Zimmermann GS, Matthes S, Meinel FG, et al. Suspected pulmonary embolism in patients with pulmonary fibrosis: discordance between ventilation/perfusion SPECT and CT pulmonary angiography. Respirology. 2016;21:1081–7. https://doi.org/10.1111/resp.12797.CrossRefPubMedGoogle Scholar
- 142.Gopalan D, Delcroix M, Held M. Diagnosis of chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017;26. https://doi.org/10.1183/16000617.0108-2016.
- 146.Begic A, Opankovic E, Cukic V, Lindqvist A, Miniati M, Bajc M. Ancillary findings assessed by ventilation/perfusion tomography. Impact and clinical outcome in patients with suspected pulmonary embolism. Nuklearmedizin. 2015;54:223–30. https://doi.org/10.3413/Nukmed-0748-15-06.CrossRefPubMedGoogle Scholar
- 153.Jögi J, Al-Mashat M, Rådegran G, Bajc M, Arheden H. Diagnosing and grading heart failure with tomographic perfusion lung scintigraphy: validation with right heart catheterization. ESC Heart Fail. 2018. https://doi.org/10.1002/ehf2.12317.
- 154.Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H, et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax. 2009;64:1062–9. https://doi.org/10.1136/thx.2008.109785.CrossRefPubMedPubMedCentralGoogle Scholar
- 159.Hofman MS, Callahan J, Eu P, Hicks RJ. Segmental hyperperfusion in lobar pneumonia visualized with respiratory-gated four-dimensional pulmonary perfusion positron emission tomography-computed tomography. Am J Respir Crit Care Med. 2014;189:104–5. https://doi.org/10.1164/rccm.201307-1196IM.CrossRefPubMedGoogle Scholar
- 161.Guérin L, Couturaud F, Parent F, Revel MP, Gillaizeau F, Planquette B, et al. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost. 2014;112:598–605. https://doi.org/10.1160/th13-07-0538.CrossRefPubMedGoogle Scholar
- 164.Tunariu N, Gibbs SJ, Win Z, Gin-Sing W, Graham A, Gishen P, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med. 2007;48:680–4. https://doi.org/10.2967/jnumed.106.039438.CrossRefPubMedGoogle Scholar
- 166.Dournes G, Verdier D, Montaudon M, Bullier E, Rivière A, Dromer C, et al. Dual-energy CT perfusion and angiography in chronic thromboembolic pulmonary hypertension: diagnostic accuracy and concordance with radionuclide scintigraphy. Eur Radiol. 2014;24:42–51. https://doi.org/10.1007/s00330-013-2975-y.CrossRefPubMedGoogle Scholar
- 174.Sivandarajah S. Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 4: current evidence does not support the use of a negative D-dimer to rule out suspected pulmonary embolism in pregnancy. Emerg Med J. 2011;28:245–6. https://doi.org/10.1136/emj.2011.111617.CrossRefPubMedGoogle Scholar
- 177.Leung AN, Bull TM, Jaeschke R, Lockwood CJ, Boiselle PM, Hurwitz LM, et al. An official American Thoracic Society/Society of Thoracic Radiology clinical practice guideline: evaluation of suspected pulmonary embolism in pregnancy. Am J Respir Crit Care Med. 2011;184:1200–8. https://doi.org/10.1164/rccm.201108-1575ST.CrossRefPubMedGoogle Scholar
- 193.Leung AN, Bull TM, Jaeschke R, Lockwood CJ, Boiselle PM, Hurwitz LM, et al. American Thoracic Society documents: an official American Thoracic Society/Society of Thoracic Radiology Clinical Practice Guideline--evaluation of suspected pulmonary embolism in pregnancy. Radiology. 2012;262:635–46. https://doi.org/10.1148/radiol.11114045.CrossRefPubMedGoogle Scholar
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.